General Information

We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Our LAL is made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet (“UV”) light generated by our LDD. With the RxSight system, the surgeon performs a standard cataract procedure to implant the LAL, determines refractive error with patient input after healing is complete, and then uses the LDD to modify the lens with the exact amount of visual correction needed to achieve the patient’s desired vision outcomes.

Employees: 171
Founded: 1997
Contact Information
Address 100 Columbia Aliso Viejo, CA 92656, US
Phone Number (949) 521-7830
Web Address http://www.rxsight.com
View Prospectus: RxSight
Financial Information
Market Cap $450.84mil
Revenues $15.27 mil (last 12 months)
Net Income $4.27 mil (last 12 months)
IPO Profile
Symbol RXST
Exchange NASDAQ
Shares (millions): 7.4
Price range $16.00 - $16.00
Est. $ Volume $117.6 mil
Manager / Joint Managers J.P. Morgan/ BofA Securities/ SVB Leerink/ Wells Fargo Securities/ BTIG
CO-Managers -
Expected To Trade: 7/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change